Every material Form 8-K Helix Acquisition Corp. III has filed with the SEC since January 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nasdaq notified Helix Acquisition Corp. III on August 14, 2026 that it does not meet the 300 Total Holders requirement for continued listing on the Nasdaq Global Market. The company says the notice is a deficiency notification, not an imminent delisting, and its Class A shares will continue to trade as HLXC.
Nasdaq notice received August 14, 2026 under Listing Rule 5452(a)(2)(A), requiring at least 300 Total Holders
Company has 45 calendar days to submit a plan to regain compliance
If accepted, Nasdaq may grant an extension of up to 180 calendar days from the notice date; otherwise the company may appeal to a Nasdaq Hearings Panel
Helix Acquisition Corp. III, a blank check company, closed its initial public offering on January 26, 2026, selling 17,250,000 Class A ordinary shares at $10.00 per share for gross proceeds of $172.5 million, including the full exercise of the underwriters' over-allotment option. The full $172.5 million was placed in a U.S.-based trust account, and the company has 24 months to complete a business combination but has not yet selected a target, so shareholder funds remain in trust rather than in an operating business.
IPO closed January 26, 2026: 17,250,000 Class A ordinary shares at $10.00 each, including 2,250,000 from the over-allotment option, for $172.5 million gross proceeds.
Concurrent private placement of 497,500 Class A shares at $10.00 each to sponsor Helix Holdings III LLC, for $4.975 million gross proceeds.
$172.5 million placed in trust account, with Continental Stock Transfer & Trust Company as trustee.
Company has 24 months from the IPO closing to complete a business combination; no target has been selected.
Helix Acquisition Corp. III, a blank-check company focused on healthcare, closed its initial public offering on January 26, 2026, selling 17,250,000 Class A ordinary shares at $10.00 per share for gross proceeds of $172.5 million, including the full exercise of the underwriters' over-allotment option. The proceeds, together with a concurrent private placement, were placed in a trust account, and the funds will not be released until the company completes an initial business combination or redeems public shares if it does not complete one within 24 months.
IPO closed January 26, 2026: 17,250,000 Class A ordinary shares at $10.00 each, gross proceeds of $172.5 million, including 2,250,000 shares from the over-allotment option
Private placement of 497,500 Class A shares to sponsor Helix Holdings III LLC at $10.00 per share, for gross proceeds of $4.975 million
Trust account holds $172.5 million; funds are released only on a business combination or on redemption if none is completed within 24 months of the IPO closing
Mark C. McKenna and John Schmid were appointed independent directors on January 22, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Helix Acquisition Corp. III filing is on SEC EDGAR ↗. 8-K briefs of other companies →